A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases

Ami N. Shah(Northwestern University), Massimo Cristofanilli(Cornell University), Jenny C. Chang(Universität Hamburg), Cesar A. Santa‐Maria(Johns Hopkins University), Shruti Chandra(Moorfields Eye Hospital NHS Foundation Trust), Anthony K. Kang(Northwestern University), Lorenzo Gerratana(National Cancer Institute), Kirsten B. Burdett(Northwestern University), William J. Gradishar(Northwestern University), Jill Woodman(Northwestern University), Priya Kumthekar(Northwestern University), Borko Jovanovic(Northwestern University), Dhruvika Mukhija(Northwestern University), Nikita Shah(Orlando Health), Dean Tsarwhas(Northwestern University)
Clinical Breast Cancer
December 15, 2022
10.1016/j.clbc.2022.12.006
Cited by 14

Related Papers

The Global Health and Economic Burden of Hospitalizations for Heart Failure
|Journal of the American College of Cardiology|2014|2k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.6k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k